Magenau, J., Pawarode, A., Buck, T., Jones, D., Kato, K., Harris, A., … Mineishi, S. (2010). Allogeneic haematopoietic cell transplantation with clofarabine/busulfan x 4 conditioning exhibits significant anti-leukaemic activity in non-remission AML. In BONE MARROW TRANSPLANTATION (Vol. 45, pp. S79–S80). Vienna, AUSTRIA: NATURE PUBLISHING GROUP.

Magenau, J., A. Pawarode, T. Buck, D. Jones, K. Kato, A. Harris, D. Frame, et al. “Allogeneic haematopoietic cell transplantation with clofarabine/busulfan x 4 conditioning exhibits significant anti-leukaemic activity in non-remission AML.” In BONE MARROW TRANSPLANTATION, 45:S79–80. NATURE PUBLISHING GROUP, 2010.

Magenau J, Pawarode A, Buck T, Jones D, Kato K, Harris A, et al. Allogeneic haematopoietic cell transplantation with clofarabine/busulfan x 4 conditioning exhibits significant anti-leukaemic activity in non-remission AML. In: BONE MARROW TRANSPLANTATION. NATURE PUBLISHING GROUP; 2010. p. S79–80.

Magenau, J., et al. “Allogeneic haematopoietic cell transplantation with clofarabine/busulfan x 4 conditioning exhibits significant anti-leukaemic activity in non-remission AML.” BONE MARROW TRANSPLANTATION, vol. 45, NATURE PUBLISHING GROUP, 2010, pp. S79–80.

Magenau J, Pawarode A, Buck T, Jones D, Kato K, Harris A, Frame D, Kujawski L, Erba H, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Braun T, Ferrara J, Levine J, Mineishi S. Allogeneic haematopoietic cell transplantation with clofarabine/busulfan x 4 conditioning exhibits significant anti-leukaemic activity in non-remission AML. BONE MARROW TRANSPLANTATION. NATURE PUBLISHING GROUP; 2010. p. S79–S80.